Back to Sites FAMCRU CRS Site Number 8950 Address FAMCRU Ward J8 Tygerberg Hospital Francie van Zijl Drive Parow Valley Tygerberg, Western Cape Province 7505 South Africa IMPAACT Members at this Site Jacqueline Jacobs CAB Member Siphokazi Khonkwane CAB Member Jeanne De Jager CRS Coordinator Shaun Barnabas CRS Leader Mark Cotton CRS Leader Ronell Arendze CRS Staff Jacky Crisp CRS Staff Jeanne De Jager CRS Staff Els Dobbels CRS Staff George Fourie CRS Staff Lindee Ganger CRS Staff Leonie Groepies CRS Staff Morne Isaacs CRS Staff Veronica Matroos CRS Staff Bongiwe Mbotho CRS Staff Nwabisa Mtambeka CRS Staff Susan Purchase CRS Staff Helena Rabie CRS Staff Magdel Rossouw CRS Staff Kurt Smith CRS Staff Marie Theunissen CRS Staff Warren Zimri CRS Staff Jeannine du Bois CTU Coordinator Anneke Hesseling CTU Principal Investigator Donna Germuga DAIDS PO Maria Groenewald Investigator Barbara Laughton Investigator Simon Schaaf Investigator Gerhard Theron Investigator Lindie Rossouw Pediatrician Catherine Andrea Pharmacist Marlize Smuts Pharmacist of Record Marjie van Schalkwyk Principal Investigator Lilly Hoorn Research Nurse Andrea Gutschmidt Staff Sharifah Sylvester Staff Marjie van Schalkwyk Study Coordinator Studies at this Site IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Enrolling IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure and Immunotherapy Study Status Enrolling IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Therapeutics Study Status Closed to Accrual IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Therapeutics Study Status Pending IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Adults with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Pending IMPAACT 2039: EXCEED DAIDS Number 38,988 Research Area Cure and Immunotherapy Study Status In Development Pagination Previous page Prev Page 1 Page 2 Current page 3
IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Enrolling
IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure and Immunotherapy Study Status Enrolling
IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Therapeutics Study Status Pending
IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Adults with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Pending
IMPAACT 2039: EXCEED DAIDS Number 38,988 Research Area Cure and Immunotherapy Study Status In Development